Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037185 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4CMEN1 | |
| SCHEMBL5257490 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4DPDE4CCYP2C9 | |
| SCHEMBL7448426 | 0.82 | PDE4A (0.56) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6989316 | 0.82 | PDE4A (0.54) | PDE4APDE4BPDE4DPDE4CCYP2C9 | |
| SCHEMBL4037497 | 0.82 | PDE4A (0.57) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL4039851 | 0.82 | PDE4A (0.54) | PDE4APDE4BPDE4DPDE4CCYP2C9 | |
| SCHEMBL4041242 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL4037954 | 0.81 | PDE4A (0.57) | PDE4APDE4BPDE4DPDE4CMEN1 | |
| SCHEMBL4037435 | 0.81 | PDE4A (0.52) | PDE4APDE4BPDE4DPDE4CMEN1 | |
| SCHEMBL4039783 | 0.79 | PDE4A (0.60) | PDE4APDE4BPDE4DPDE4CCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4D 5/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | PDE4A 4658/4885PDE4B 4639/4885PDE4D 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.